Parasitic Diseases: Clinical Trials

368 trials for Parasitic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

268 completed, 35 unknown, 21 terminated, 15 not yet recruiting. 368 Phase 3, 68 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3368Completed 268, Unknown 35, Terminated 21, Not yet recruiting 15, Recruiting 12, Active not recruiting 9, Withdrawn 7, Suspended 1
Phase 268Completed 45, Terminated 8, Unknown 6, Not yet recruiting 4, Withdrawn 4, Active not recruiting 1

Follow Parasitic Diseases: new trials by email Literature Review of Parasitic Diseases trials Research Report on Parasitic Diseases

Trials (filtered) newest first · largest first

All 368 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren
Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria
Phase 3Not yet recruitingIndiana University15002028-01-012026-09-01
Follow-up Assessment of Change in Soil-transmitted Helminths Infection Intensity in Uganda
Albendazole 400mg, Ivermectin 3 mg - Ascariasis
Phase 3Not yet recruitingJennifer Keiser4502027-02-012026-11-17
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin - Cutaneous Leihmaniasis
Phase 3Not yet recruitingInstitute of Tropical Medicine, Belgium9002027-01-012026-03-10
Nitazoxanide for Treatment of Cryptosporidium in Children
Nitazoxanide, Placebo - Cryptosporidiosis
Phase 3Not yet recruitingJohns Hopkins Bloomberg School of Public Health4802026-12-302026-09-28
Oxfendazole in Mild Parenchymal Brain Cysticercosis
Oxfendazole single dose, Oxfendazole three doses, albendazole plus praziquantel regime - Brain Cysticercosis
Phase 2 / Phase 3Not yet recruitingUniversidad Peruana Cayetano Heredia5442026-12-012026-05-01
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
emodepside (BAY 44-4400), Mebendazole 100 MG, similar placebo to mebendazole - Trichuris Trichiura; Infection, Hookworm Infection
Phase 3Not yet recruitingSwiss Tropical & Public Health Institute3152026-11-062026-08-14
Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis
Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni
Phase 2 / Phase 3Not yet recruitingRhode Island Hospital6002026-11-012026-08-12
Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras
Placebo, Albendazole 400 mg, Albendazole Plus Ivermectin - Trichuriasis, Strongyloidiasis
Phase 3Not yet recruitingMundo Sano Foundation3682026-11-012026-06-23
Better Options for Lymphatic Filariasis Treatment
MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole, IDA - Ivermectin + DEC + albendazole - Lymphatic Filariasis, Scabies
Phase 3RecruitingMedicines Development for Global Health51002026-09-282026-10-07
Efficacy of Diloxanide Furoate as Additional Luminal Agent Along With Metronidazole for the Treatment of Amoebic Liver Abscess
Diloxanide furoate, Placebo - Liver Abscess, Amoebic Liver Abscess
Phase 3Not yet recruitingPost Graduate Institute of Medical Education and Research, Chandigarh2202026-09-042026-09-10
An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria
High dose ultra short Primaquine, Placebo - Malaria
Phase 3Not yet recruitingMenzies School of Health Research10192026-06-012026-03-12
Postpartum 8-aminoquinoline Breast Milk Study
Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort - Drug Pharmacokinetics in Healthy Volunteers
Phase 2 / Phase 3Not yet recruitingCurtin University602026-04-012026-03-18
Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.
Arnica Tincture, Meglumine antimoniate. - Leishmaniasis, Cutaneous
Phase 3RecruitingUniversidad de Antioquia962026-03-112026-04-02
Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections
emodepside (BAY 44-4400), matching placebo of emodepside, Mebendazole - Trichuris Trichiura; Infection, Hookworm Infection
Phase 3CompletedSwiss Tropical & Public Health Institute3152025-11-252026-10-08
Safety of Antimalarials in the FIRst trimEster
dihydroartemisinin-piperaquine (DP), Pyronaridine-artesunate (PA), Artemether-lumefantrine - Malaria, Pregnancy, Malaria, Antepartum
Phase 3RecruitingLiverpool School of Tropical Medicine15102025-09-302025-11-19
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
Pre-screening Phase, Screenig Phase, Randomization - Soil-Transmitted Helminths
Phase 3RecruitingInsud Pharma200002025-09-012025-09-15
STI Testing to Enhance PrEP Use in Pregnancy
Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis testing - PrEP Adherence, Sexually Transmitted Infections (STIs)
Phase 3RecruitingBotswana Harvard AIDS Institute Partnership6002025-06-182026-06-11
Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
PvSeroTAT, Control - Malaria Vivax, Malaria Falciparum
Phase 3RecruitingLondon School of Hygiene and Tropical Medicine192002025-05-122026-09-18
Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Discharge
Antimalarial monoclonal antibodies, Dihydroartemisinin - Piperaquine (DP), Placebo mMAB - Malaria, Severe Malaria
Phase 3Active not recruitingLiverpool School of Tropical Medicine3982025-05-022026-08-05
Antimicrobial Adjuvants to Revert the Imbalance of Skin Microbiota for Improved Outcomes of Complicated Cutaneous Leishmaniasis Treatment in Ethiopia
Fusidic Acid, Vehicle cream - Leishmaniasis, Cutaneous
Phase 3Not yet recruitingInstitute of Tropical Medicine, Belgium1802025-04-012024-11-19

Showing 20 of 368. Sign in to see all of them.

Narrower conditions

Malaria (169)  ·  Malaria, Falciparum (60)  ·  Leishmaniasis, Cutaneous (24)  ·  Malaria, Vivax (22)  ·  Scabies (14)  ·  Anemia (13)  ·  Chagas Disease (13)  ·  Leishmaniasis, Visceral (13)  ·  Schistosomiasis (10)  ·  Lice Infestations (9)  ·  Trypanosomiasis, African (9)  ·  Elephantiasis, Filarial (8)  ·  HIV Infections (8)  ·  Trichuriasis (8)  ·  Ancylostomiasis (7)

Broader conditions

Infections (362)  ·  Protozoan Infections (291)  ·  Vector Borne Diseases (289)  ·  Mosquito-Borne Diseases (212)  ·  Euglenozoa Infections (66)  ·  Skin and Connective Tissue Diseases (59)  ·  Skin Diseases (58)  ·  Skin Diseases, Infectious (58)  ·  Skin Diseases, Parasitic (58)  ·  Helminthiasis (52)  ·  Malaria (37)  ·  Leishmaniasis (35)  ·  Nematode Infections (31)  ·  Secernentea Infections (29)

Interventions

fanasil, pyrimethamine drug combination (40)  ·  Artemether, Lumefantrine Drug Combination (36)  ·  Albendazole (29)  ·  Chloroquine (28)  ·  Ivermectin (25)  ·  Primaquine (21)  ·  Amodiaquine (19)  ·  Artesunate (19)  ·  Praziquantel (14)  ·  miltefosine (14)  ·  Azithromycin (13)  ·  Meglumine Antimoniate (12)  ·  Paromomycin (11)  ·  amodiaquine, artesunate drug combination (11)  ·  pyronaridine tetraphosphate, artesunate drug combination (11)

Sponsors

London School of Hygiene and Tropical Medicine (53)  ·  Drugs for Neglected Diseases (14)  ·  University of Oxford (14)  ·  Institute of Tropical Medicine, Belgium (12)  ·  University of California, San Francisco (12)  ·  GlaxoSmithKline (11)  ·  Menzies School of Health Research (8)  ·  Liverpool School of Tropical Medicine (7)  ·  Jennifer Keiser (6)  ·  Medicines for Malaria Venture (6)  ·  Pfizer (6)  ·  Makerere University (5)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (5)  ·  Oswaldo Cruz Foundation (5)  ·  Barcelona Institute for Global Health (4)

Countries

Uganda (36)  ·  Kenya (34)  ·  Burkina Faso (32)  ·  Tanzania (28)  ·  Brazil (26)  ·  Ghana (22)  ·  United States (21)  ·  Democratic Republic of the Congo (20)  ·  Mali (19)  ·  India (18)  ·  Ethiopia (14)  ·  The Gambia (14)  ·  Colombia (13)  ·  Côte d’Ivoire (11)  ·  Malawi (11)

Top investigators

Grant Dorsey, MD, PhD (6)  ·  Diane V Havlir, MD (4)  ·  Brian Greenwood, FRCP, FRS (3)  ·  Brian Greenwood, MD (3)  ·  Eric Ottesen, MD (3)  ·  Jayaram Menon, MBBS (3)  ·  Nigel Hill, PhD (3)  ·  Paul J Milligan, PhD (3)  ·  Shyam Sundar, MD (3)  ·  Tsin Yeo, MBBS (3)  ·  Alassane Dicko, Professor (2)  ·  Arjen Dondorp, MD (2)  ·  Armando O. Schubach, MD, PhD (2)

Results publications

PMID 39324693, PMID 23433102, PMID 26666916, PMID 11873261, PMID 22610930, PMID 32228663, PMID 10656038, PMID 17845167, PMID 21849081, PMID 22993389, PMID 25425434, PMID 28379954, PMID 29324864, PMID 29547881, PMID 33020153, PMID 35732155, PMID 36534705, PMID 8937280, PMID 9790423, PMID 11500748, PMID 12095806, PMID 12510893, PMID 16235350, PMID 16503464, PMID 16551365, PMID 16640611, PMID 16702588, PMID 17046467, PMID 17128343, PMID 17239256, PMID 17519409, PMID 17519410, PMID 17582067, PMID 17940319, PMID 17958887, PMID 17971864, PMID 18074034, PMID 18171245, PMID 18213379, PMID 18237394, PMID 18414647, PMID 18495737, PMID 18522503, PMID 18547415, PMID 18547416, PMID 18582194, PMID 18598190, PMID 18620950, PMID 18682739, PMID 18752443

NIH funding

P01HD059454 (2), 2008 (1), 2009 (1), 2016 (1), 2019 (1), 2023 (1), R01AI104702 (1), R01AI155739 (1), R01AI184979 (1), R01NS054805 (1), U01AI126610 (1), U01AI138910 (1), U01AI155325 (1), U01AI157962 (1), U01AI167788 (1)